Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (PL)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 1, January-February, p. 113–121

Publication type: review article

Language: Polish

Rola Chlamydophila pneumoniae w astmie oskrzelowej i przewlekłej obturacyjnej chorobie płuc – mechanizmy odpowiedzi immunologicznej

The Role of Chlamydophila pneumoniae in Asthma and Chronic Obstructive Pulmonary Disease – Immunological Response Mechanism

Agnieszka Jama−Kmiecik1,, Irena Choroszy−Król1,

1 Zakład Nauk Podstawowych AM we Wrocławiu

Streszczenie

Chlamydophila pneumoniae jest wewnątrzkomórkowym patogenem, który przyczynia się do zakażeń górnych i dolnych dróg oddechowych. Jest drobnoustrojem występującym w dwóch formach: zakaźnej (ciałko elementarne) oraz metabolicznie aktywnej (ciałko siateczkowate). Przeciwciała przeciwko C. pneumoniae wykrywa się u 50–80% badanych pacjentów na całym świecie. Komórkowa odpowiedź immunologiczna jest kluczową odpowiedzią gospodarza przeciw Chlamydophila. Komórki CD4 i CD8 pełnią główną rolę ochronną przed zakażeniem tym drobnoustrojem. Prowadzone badania wskazują na udział C. pneumoniae w rozwoju, a także nasileniu chronicznej i ostrej astmy. Zakażenia C. pneumoniae przyczyniają się również do nasilenia objawów przewlekłej obturacyjnej choroby płuc.

Abstract

Chlamydophila pneumoniae is an intracellular pathogen that causes upper and lower respiratory tract infection. This microorganism can exists in 2 forms: an infectious form (elementary bodies) and a metabolic form (reticulate bodies). Antibodies against C. pneumoniae are found in 50–80% of adults surveyed around the world. Cell−mediated immunity is crucial in host defenses against Chlamydia. Both CD4 and CD8 T cell have shown to be needed for efficient protection against Chlamydophila. Many studies have implicated C. pneumoniae in the development and exacerbation of both chronic and acute asthma. C. pneumoniae infection is associated with exacerbations of chronic obstructive pulmonary disease too.

Słowa kluczowe

Chlamydophila pneumoniae, astma, przewlekła obturacyjna choroba płuc

Key words

Chlamydophila pneumoniae, asthma, chronic obstructive pulmonary disease

References (78)

  1. Kosma P: Chlamydial lipopolysaccharide. Bioch Bioph Acta 1999, 1455, 387–402.
  2. CotterTW, Byrne GI: Immunity to Chlamydia: comparison of human infections and murine models, Department of Medical Microbiology and Immunology. University of Wisconsin Medical School 1996, 13, 587–594.
  3. Cox RL, Kuo CC, Grayston JT, Campbell LA: Deoxyrybonucleic acid relatedness of Chlamydia trachomatis and Chlamydia psittaci. Ind J Syst Bacteriol 1988, 38, 265–268.
  4. Vanrompay D, Ducatelle R, Haesebrouck F: Chlamydia infections: a review with emphasis on avian chlamydiosis. Vet Microbiol 1995, 45, 93–119.
  5. Fukushi H, Hirai K: Chlamydia pecorum – the fourth species of genus Chlamydia. Microbiol Immunol 1993, 37, 515–522.
  6. Kuo CC, Jackson LA, Campbell LA, Grayston JT: Chlamydia pneumoniae (TWAR), Clin Microb Rev, 1995, 8, 451–461.
  7. Schito GC: Incidence of lower respiratory tract infections caused by Mycoplasma, Chlamydia and Legionella, An Italia Multicenter Survey. J Chemiother 1994, 63, 19–21.
  8. Moulder JW: Interaction of Chlamydiae and host cells in vitro. Microbiol Rev 1991, 55, 143–190.
  9. Newhall WJ: Biosynthesis and disulfide cross−linking of outer−membrane components during the growth cycle of Chlamydia trachomatis. Infect Immun 1987, 55, 162–168.
  10. Kuo CC, Takakashi N, Swanson AF, Ozeki Y, Hakemori S: An n−linked high−mannose type oligosaccharide, expressed at the major outer membrane protein of Chlamydia trachomatis, mediates attachment and infectivity of the microorganism to HeLa cells. J Clin Invest 1997, 98, 2813–2818.
  11. Su H, Raymond I, Rockey DD, Fischer E, Hackstadt T, Caldwell HD: A recombinant Chlamydia trachomatis major outer membrane protein binds to heparin sulfate receptors on epithelials cells. Proc Natl Acad Sci USA 1996, 93, 11143–11148.
  12. Ward ME: The immunobiology and immunopathology of chlamydial infection. APMIS 1995, 103, 769–796.
  13. Raulston JE: Chlamydial envelope components and pathogen−host cell interactions. Mol Microbiol 1995, 15, 607–616.
  14. Matsumoto A: Structural characteristics of chlamydial bodies. In: Microbiology of Chlamydia. CRC Press Boca Raton Fl. 1988, 21–45.
  15. Kaltenboeck B, Kosoulas KG, Storz JP: Structures of and allelic diversity and relationships among the major outer membrane protein (ompA) genes of the four chlamydial species. J Bacteriol 1993, 175, 487–502.
  16. Ossewaarde JM: Introducing Chlamydophila pneumoniae: the TWAR agent Chlamydia pneumoniae in a new perspective. Netherlands J Med 2001, 59, 41–44.
  17. Troy CJ, Peeling RW, Ellis AC: Chlamydia pneumoniae as a new source of infections outbreaks in nursing homes. JAMA 1997, 227, 1214.
  18. Johnston SL, Martin RJ: Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis? Am J Respir Crit Care Med 2005, 172 (9), 1078–1089.
  19. Correia P, Brito MJ, Neves C, Ferreira GC, Machado Molo C: Respiratory infection caused by Chlamydia pneumoniae, Acta Med Port 2005, 18 (5), 315–321.
  20. Martin RJ: Infections and asthma. Clin Chest Med 2006, 27(1), 87–98.
  21. De Barbeyrae B, Bebear C: Chlamydial pathogenesis: diagnostic and therapeutic consequences. Arch Pediatr 2005, 12 (1), S26–31.
  22. Raymond J: Chlamydia infections: diagnostic procedures. Arch Pediatr 2005, 12 (1), S42–44.
  23. De Ory F, Guisasola ME, Eiros JM: Detection of Chlamydophila pneumoniae IgG in paired serum samples: comparison of serological techniques in pneumonia cases, APMIS 2006, 114 (4), 279–284.
  24. Boman J, Gaydos CA, Quinn TC: Molecular diagnosis of Chlamydia pneumoniae infection. J Clin Microbiol 1999, 37 (12), 3791–3799.
  25. Von Hertzen LC: Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J 2002, 19, 546–556.
  26. Svanholm C, Bandholtz L, Castanos−Velez E, Wigzell H: Protective DNA immunization against Chlamydia pneumoniae. Scand J Immunol 2000, 51, 345–353.
  27. Stratton ChW, Mitchell WM: The immunopathology of chlamydial infections. Antimicrob Infect Dis New 1997,16, 89–94.
  28. Halme S, Surcel H−M: Cell mediated immunity to Chlamydia pneumoniae. Scand J Infect Dis 1997, 104, 18–21.
  29. Huittinen T, Hahn D, Anttila T, Wahlstrom E, Saikku P, Leinonen M: Host immune response to Chlamydia pneumoniae heat shock protein 60 is associated with asthma. Eur Respir J 2001, 17, 1078–82.
  30. Takano R, Yamaguchi H, Sugimoto S, Nakamura S, Friedman H, Yamamoto Y: Cytokine response of lymphocytes persistently infected with Chlamydia pneumoniae. Curr Microbiol 2005, 50(3), 160–166.
  31. Halme S, Latvala J, Karttunen R, Palatsi I, Saikku P, Surcel HM: Cell−mediated immune response during primary Chlamydia pneumoniae infection. Infect Immun 2000, 68, 7156–7158.
  32. Wark PA, Johnston SL, Moric I, Simpson JL, Hensley MJ, Gibson PG: Neutrophil degranulation and cell lysis is associated with clinical severity in virus−induced asthma. Eur Respir J 2002, 19, 68–75.
  33. Bailey RL, Holland MJ, Whittle HC, Mabey DC: Subjects recovering from human ocular chlamydial infection have enhanced lymphoproliferative responses to chlamydial antigens compared with those of persistently diseased controls. Infect Immun 1995, 63, 389–392.
  34. Igietseme JU, Ramsey KH, Magee DM, Wiliams DM, Kincy TJ, Rank RG: Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar−specific, Th1 lymphocyte clone. Reg Immunol 1993, 5, 317–324.
  35. Magee DM, Igietseme JU, Smith JG, Bleicker CA, Grubbs BG, Schachter J, Rank RG, Wiliams DM: Chlamydia trachomatis, pneumoniae in the severe combined immunodeficiency (SCID) mouse. Reg Immunol 1993, 5, 305–311.
  36. Darville T, Andrews JrCW, Sikes JD, Fraley PL, Braswell L, Rank RG: Mouse strain−dependent chemokine regulation of the genital tract T helper cell type 1 immune response. Infect Immun 2001, 69, 7419–7424.
  37. Penttila JM, Anttila M, Puolakkainen M, Laurila A, Varkila K, Sarvas M, Makela: BALB/c mice during primary infection and reinfection. Infect Immun 1998, 66, 5113–5118.
  38. Prescott SL, Macaubas C, Bolt BJ, Smallacombe TB, Loh R, Sly PD, Holt PG: Local immune responses to Chlamydia pneumoniae in the lungs of Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. J Immunol 1998, 160, 4730–4737.
  39. Kovarik J, Siegrist CA: Immunity in early life. Immunol Today 1998, 19, 150–152.
  40. Adkins B: T−cell function in newborn mice and humans. Immunol Today 1999, 20, 330–335.
  41. Marodi L: Down−regulation of Th1 responses in human neonates. Clin Exp Immunol 2002, 128, 1–2.
  42. Adkins B, Hamilton K: Freshly isolated, murine neonatal T cells produce IL−4 in response to anti−CD3 stimulation. J Immunol 1992, 149, 3448–3455.
  43. Ribeiro−do−Couto LM, Boeije LC, Kroon JS, Hooibrink B, Breur−Vriesendorp BS, Aarden LA, Boog CJ: High IL−13 production by human neonatal T cells: neonate immune system regulator? Eur J Immunol 2001, 31, 3394–3402.
  44. Adkins B, Ghanei A, Hamilton K: Developmental regulation of IL−4, IL−2, and IFN−gamma production by murine peripheral T lymphocytes. J Immunol 1993, 151, 6617–6626.
  45. Gaydos CA: Growth in vascular cells and cytokine production by Chlamydia pneumonia. J Infect Dis 2000, 181 (suppl 3), 473–478.
  46. Bot A, Antohi S, Bona C: Immune response of neonates elicited by somatic transgene vaccination with naked DNA. Front Biosci 1997, 2, 173–188.
  47. Światowa Strategia Leczenia i Rozpoznawania, Leczenia i Prewencji Astmy. GINA WHO NHLBI 2002.
  48. Grayston JT: Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992, 15, 757–761.
  49. Kalayoglu MV, Libby P, Byrne GI: Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002, 288, 2724–2731.
  50. Hammerschlag MR: Chlamydia pneumoniae and the lung. Eur Respir J 2000, 16, 1001–1007.
  51. Kraft M: The role of bacterial infections in asthma. Clin Chest Med 2000, 21, 301–313.
  52. Gencay M, Rudiger JJ, Tamm M, Soler M, Perruchoud AP, Roth M: Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma. Am J Respir Crit Care Med 2001, 163, 1097–1100.
  53. Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH: A link between chronic asthma and chronic infection. J Allergy Clin Immunol 2001, 107, 595–601.
  54. Ten Brinke A, van Dissel JT, Sterk PJ, Zwindermann AH, Rabe KF, Bel EH: Persistent airflow limitation in adult−onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection. J Allergy Clin Immunol 2001, 107, 449–454.
  55. Clementsen P, Permin H, Norn S: Chlamydia pneumoniae infection and its role in asthma and chronic obstructive pulmonary disease. J Invest Allergol Clin Immunol 2002, 12, 73–79.
  56. Hahn L, Anttila T, Saikku P: Associaton of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma. Epidemiol Infect 1996, 117, 513–517.
  57. Hahn DL, McDonald R: Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic asthma? Ann Allergy Asthma Immunol 1998, 81, 339–344.
  58. Cunningham AF, Johnson SL, Julious SA, Lampe FC, Ward ME: Chronic Chlamydia pneumoniae infection and asthma exacerbations in children. Eur Respir J 1998, 11, 345–349.
  59. Cook PJ, Davies P, Tnnicliffe W, Ayres JG, Honeybourne D, Wise R: Chlamydia pneumoniae and asthma. Thorax 1998, 53, 254–259.
  60. Von Hertzen L, Toyryla M, Gimishanov A, Bloigu A, Leinonen M, Saikku P, Haahtela T: Asthma, atopy and Chlamydia pneumoniae antibodies in adults. Clin Exp Allergy 1999, 29, 522–528.
  61. Black PN, Scicchitano R, Jenkins CR, Blasi F, Allegra L, Wlodarczyk J, Cooper BC: Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 2000, 15, 254–259.
  62. Morrison RP: Chlamydial hsp60 and the immunopathogenesis of chlamydial disease. Semin Immunol 1991, 3, 25–33.
  63. Betsou F, Sueur JM, Orfila J: Anti−Chlamydia pneumoniae heat shock protein 10 antibodies in asthmatic adults. FEMS Immunol Med Microbiol 2003, 35, 107–111.
  64. Holland MJ, Bailey RL, Hayes LJ, Whittle HC, Mabey DC: Conjunctival scarring in trachoma is associated with depressed cell−mediated immune responses to chlamydial antigens. J Infect Dis 1993, 168, 1528–1531.
  65. Rottenberg ME, Gigliotti Rothfuchs AC, Gigliotti D, Svanholm C, Bandholtz L, Wigzell H: Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J Immunol 1999, 162, 2829–2836.
  66. Heath PT: Epidemiology and bacteriology of bacterial pneumonias. Paediatr Respir Rev 2000, 1, 4–7.
  67. Von Hertzen L: Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J 2002, 19, 546–556.
  68. Shemer−Avni Y, Lieberman D: Chlamydia pneumoniae−induced ciliostasis in ciliated bronchial epithelial cells. J Infect Dis 1995, 171, 1274–1278.
  69. Wark PA, Johnston SL, Simpson JL, Hensley MJ, Gibson PG: Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma. Eur Respir J 2002, 20, 834–840.
  70. Coombes BK, Johnson DL, Mahony JB: Strategic targeting of essential host−pathogen interactions in chlamydial disease. Curr Drug Targets Infect Disord 2002, 2, 201–216.
  71. Blotta MH, DeKruyff RH, Umetsu DT: Corticosteroids inhibit IL−12 production in human monocytes and enhance their capacity to induce IL−4 synthesis in CD4+ lymphocytes. J Immunol 1997, 158, 5589–5595.
  72. Laitinen K, Laurila AL, Leinonen M, Saikku P: Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment. Infect Immun 1996, 64, 1488–1490.
  73. Senior RM, Anthonisen NR: Chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1998, 157, 139–147.
  74. Snider GL: Chronic obstructive pulmonary disease: risk factors, pathophysiology, and pathogenesis. Ann Rev Med 1989, 40, 411–429.
  75. Zalacain R: Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999, 13, 343–348.
  76. Hertzen von LC: Chlamydia pneumoniae and its role in chronic obstructive pulmonary disease. Ann Med 1998, 30, 27–37.
  77. Laurila A: Chlamydia pneumoniae and chronic lung diseases. Scand J Infect Dis Supl 1997, 104, 34–36.
  78. Theegarten D: Does Chlamydia pneumoniae infection play a key role in pathogenesis of pulmonary emphysema? Proceedings Four Meeting of the European Society for Chlamydia Research. Helsinki, Finland, 2000, 319.